首页> 美国卫生研究院文献>Cancers >Genomic Fabric Remodeling in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): A New Paradigm and Proposal for a Personalized Gene Therapy Approach
【2h】

Genomic Fabric Remodeling in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): A New Paradigm and Proposal for a Personalized Gene Therapy Approach

机译:转移性透明细胞肾细胞癌(CCRCC)的基因组织物质重塑:个性化基因治疗方法的新范式和提案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We applied the genomic fabric principles for personalized gene therapy to a case of clear cell renal cell carcinoma (ccRCC). Despite decades of research, the process of finding the molecular mechanisms responsible for the disease and, more importantly, the therapeutic solution is still a work in progress. We analyzed the transcriptomes of the chest wall metastasis, two distinct cancer nodules, and the cancer-free surrounding tissue in the surgically removed right kidney of a Fuhrman grade 3 metastatic ccRCC patient. The studies revealed that even histopathologically equally classified cancer nodules from the same kidney have different transcriptomic topologies, requiring tailored therapeutic solutions not only for each patient but even for each cancer nodule. We identified death-associated protein kinase 3 (DAPK3); transcription activation suppressor (TASOR); family with sequence similarity 27, member C, long non-coding RNA (FAM27C); and UDP-N-acetylglucosaminyltransferase subunit (ALG13) as the gene master regulators of the four profiled regions and proposed molecular mechanisms by which expression manipulation of TASOR and ALG13 may selectively destroy the cancer cells without affecting many of the normal cells.
机译:我们将个性化基因疗法应用于透明细胞肾细胞癌(CCRCC)的案例。尽管有数十年的研究,但寻找对疾病负责的分子机制的过程,更重要的是,治疗方法仍然是正在进行的工作。我们分析了胸壁转移,两种不同的癌细节,以及富列曼3级转移性CCRCC患者的手术右肾中无癌症周围组织的转录组。这些研究表明,甚至来自同一肾的组织病理学上同样分类的癌细节均具有不同的转录组拓扑,不仅需要针对每位患者的定制治疗溶液,但即使对于每种癌症结节也是如此。我们鉴定了死亡相关的蛋白激酶3(DAPK3);转录激活抑制剂(Tasor);系列具有序列相似性27,成员C,长编码RNA(FAM27C);和UDP-N-乙酰甘氨酸氨基氨基转移酶亚基(ALG13)作为四种成型区域的基因母稳态因子和所提出的分子机制,通过该分子机制可以选择性地破坏癌细胞而不影响许多正常细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号